Lepodisiran for Cardiovascular Disease

(ACCLAIM-CTA Trial)

This trial tests a treatment called lepodisiran to determine its effectiveness for individuals with high levels of lipoprotein(a) (Lp(a)), a protein that increases heart disease risk. The study compares lepodisiran to a placebo and uses specialized heart imaging to assess effects on heart vessel plaque. It seeks participants with high Lp(a) levels who either have or are at risk for heart disease and maintain stable cholesterol medication use. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to potentially groundbreaking heart disease treatment.

If you are taking lipid-lowering medications like statins, niacin, or PCSK9 inhibitors, you need to have been on a stable dose for at least 8 weeks before joining the trial. The protocol does not specify about other medications, so it's best to discuss with the trial team.

Research has shown that lepodisiran is generally safe for people. In earlier studies, participants experienced no serious side effects from the treatment. For instance, one study found no more side effects than a placebo, a harmless pill used for comparison. Another study demonstrated that lepodisiran can lower levels of lipoprotein(a) in the blood, which might benefit heart health. These results suggest that the treatment is safe for most people, though individual experiences may vary.¹²³⁴⁵

Unlike the standard treatments for cardiovascular disease, which often include oral medications like statins and beta-blockers, lepodisiran is administered subcutaneously. This delivery method may offer more consistent drug levels in the body. Additionally, lepodisiran could work through a novel mechanism that targets specific pathways in cardiovascular health, potentially offering benefits beyond those of current options. Researchers are excited because these features might lead to improved outcomes and greater convenience for patients.

Studies have shown that lepodisiran can significantly lower lipoprotein(a) levels in the blood. In earlier research, patients experienced reductions of up to 97%. Another study found that a single dose lowered levels by 94% after 60 days. These reductions can last up to a year, highlighting the treatment's strong potential. In this trial, participants will receive either lepodisiran or a placebo to further evaluate its effectiveness and safety. So far, lepodisiran has been safe and well-tolerated. These findings suggest it could be a promising option for people with high lipoprotein(a) and an increased risk of heart disease.¹²⁵⁶⁷